17: Pioneering In The Emerging Field Of Digital Therapeutics – Scott Xiao : 17

The Emerging Biotech Leader
The Emerging Biotech Leader
17: Pioneering In The Emerging Field Of Digital Therapeutics - Scott Xiao : 17

“I won’t say that we had this all planned out because when I started, it was just a crazy idea that we were excited about, but it ended up working out really well where we’re trying to create a new class of medicine with digital therapeutics or with prescription digital therapeutics.” Scott Xiao, Co-Founder and CEO, Luminopia.

What’s possible when you think about leveraging technology to drastically improve a condition that hasn’t seen innovation or adaptation to the standard of care in 30-40 years?

If your name is Scott Xiao, the answer is launching a biotech company called Luminopia where children between the ages of 4-7 years old can now overcome suppression in their visual cortex without having to wear an eye patch or utilize atrophy drops. Through virtual reality, Luminopia treats amblyopia, commonly known as lazy eye–the leading cause of vision loss in young adults. One and a half years ago, Luminopia received FDA approval and now has their sights set on serving patients outside of the U.S.

In Episode 17 of the Emerging Biotech Leader podcast, Kim, Ramin and Scott discuss how a small and mighty team of 5-6 people made it through to commercialization while addressing an unmet need and creating a new class of medicine.

On The Team’s Mantra Going Into This

Scott started off as an undergraduate at Harvard with no prior experience in biotech. By all accounts, he has now made it past several critical inflection points and Luminopia’s impact is multiplying. Scott and his team have secured partnerships with the leading pediatric Ophthalmologists, media companies such as Sesame Street and notable investors.

But how did all of this come to be? Scott had a close friend who experienced amblyopia and through this friend, learned that the standard of care for amblyopia is an eye patch.

“One of our mantras going into this whole endeavor was ‘we can’t take technology and go out looking for a problem to tackle.’ You’re never going to be successful with that approach. So it was more about, ‘hey, we realize that there’s an unmet need in this very prevalent condition.’ We realized that technology, specifically VR, can actually have an impact. Let’s go out there and build something to make a better treatment.”

Scott and his team knew they were onto something big when they took their initial prototype to Dr. David Hunter, the chief of Ophthalmology at Boston Children’s Hospital. “He was kind enough to take the meeting and spent a whole hour with us. And he was the one that really said, ‘Look, you’re on to something.’”

By then, Scott felt confident that his technology could enable a new modality and treatment that wasn’t previously possible. As Kim puts it: this also wasn’t a matter of taking baby steps, or making a small improvement for the condition. “This was a leapfrog effect. How did you deduce that you were ready to take this on?”

On Building A Biotech: Which Way Should You Operate

Scott is the first to admit, although this was a “simple decision”–it hasn’t been a straight path. While the benefits of Luminopia’s technology were clear given their targeted, immersive manner, there were clinical trials to be had, FDA approval to be obtained and challenges to overcome.

“Although we are a small but mighty team, we had the support and guidance and worked with people who had done this before.”

One of the key areas Scott sought guidance on was Regulatory.

Listen to the episode for Scott’s quick story on meeting the Head of Luminopia’s clinical team and how he, (Scott), crash coursed his way through learning the ins and outs of a feasibility analysis. 

As you’ve heard from other guests on the podcast, Scott had many stakeholders to consider: patients, parents and the pediatric Ophthalmologists for starters.

“We knew instinctively that in order for this technology to have an impact on patients, we needed the physicians to be intimately involved in that process because the pediatric Ophthalmologists and the Optometrists are the ones that drive practice and drive management of the condition.”

To inform and help other listeners of the show planning for their own Clinical trial milestone, Ramin asked Scott to elaborate. How did he and his team obtain 23 sites and robust clinical trial data? Once again, Scott shared more on navigating a regulated space and what type of evidence was required. Be sure to listen for the answer.

As a quick easter egg: it was “easier” for the Luminopia team to run Clinical trials given the unmet need. There was also upside due to a virality quotient, also known as word of mouth, given how small the community of pediatric Opthamologists is–approximately 1200 practitioners give or take. They all wanted to bring Luminopia to their patients and referred doctors across a mix of locations throughout the U.S.

On Maintaining Hyper Efficiency

One of the key questions Scott and his team had to decide up front was which way to operate: lean, agile and moving at the speed of light like a tech company? Or, adhering to more of the thoroughness and linear approach of a healthcare company?

Luminopia did a blend of both, skewing more towards the Pharma mold of working in a step like progression but also while evaluating which areas of their business they could do differently.

“We knew that we needed to go through the same level of rigor when it came to clinical development as a traditional biopharma company, but because of the space we’re in, because our technology works, (the fact that it’s safe and doesn’t have any serious adverse effects), we could be a lot more efficient with how we ran the trial.”

In running his company with this blended approach, the advantages for the Luminopia team, or any biotech for that matter are, in Scott’s own words, “we can figure out what’s working well, what we need to tweak and then scale as we go.”

And scale they will! Listen to to hear where Luminopia is focusing next, both in patient population as well as geography and treatments, with traumatic brain injury and stroke treatment at the forefront.

Final Thoughts on GTM for Biotech

As things started to wind down, Scott answered another question on operations and execution, this time from Ramin and specific to go-to-market. “Why do you think go-to-market in digital health is challenging in pharma/pharmaceutical?”

Scott’s honest answer was this: the culture and DNA of both could not be more different. Healthcare is complex. You have to tailor the GTM to the space that you’re in and the product that you have.

“It’s also challenging because the Venn diagram, the overlap between people that have deep health care experience and people that have true consumer tech or enterprise tech experience, that overlap is not very big either. Right? So what types of people are you actually hiring and who can provide the right mix of perspectives for you to tackle these challenges?”

Hiring and assessing your team’s strengths are a big piece of the puzzle on the path towards commercialization. To keep your company efficient, growing and on the right trajectory, Scott encourages what we’ve often heard echoed before: double down on gaining different perspectives be that from patients, parents, partners and physicians.

Interested and passionate about digital medicine? Check out Episode 10, “What Is the Future of Digital Medicine” with Jen Seda, M.D. 

Stay In Touch with SSI

Our goal is to provide useful and poignant content at a few key points throughout the year. If you would like to see an example of the type of information we share, view our most recent issue of Wavelengths.